However, it should be noted that differentiative properties of ATRA were first described in HL-60 cell line [4] established from peripheral blood of a patient suffering from AML-M2 which actually lack the PML-RARA rearrangement, and several studies showed that ATRA may drive leukemic cells efficiently into differentiation and/or apoptosis in a subset of non-APL AML patients [5]. Here, RARA is linked to acute myeloid leukemia.